Minnesota mandates new drug price transparency for manufacturers and public postings.

HB 12 17, a bill to increase transparency and oversight of pharmacy benefit managers, was reported with amendments after the committee removed a fiduciary‑duty standard in favor of good‑faith/fair‑dealing language and accepted technical changes.

Citing Department of Justice and multistate investigations into alleged price fixing and market division among generic drug manufacturers, the Franklin County Legislature authorized the county to join the civil action and to retain Napoli Shkolnik PLLC as special counsel to represent county interests.

An agency official opened a two-day conference on generic drugs, framing affordability as an access issue and urging policies to make generics and biosimilars more available to Americans.

At a Cabinet meeting the president announced what he called a most-favored-nation policy and said drugmakers agreed to prices that will cut many U.S. prescription costs; the Health official present said 16 of 17 companies have reached agreements and rural health funding will support access.

Senate advances bill preventing drug companies from obstructing generic drug approvals.

Committee adopts substitute bill restricting pharmaceutical discrimination against 340B covered entities.

Representative Leitner urged committee approval of HB 4839 to prioritize generics and biosimilars in Medicaid, citing sample savings; House Fiscal said Michigan pays roughly $4.1 billion in pharmacy costs with $2.4 billion in rebates and estimated gross savings of $5000 million but noted lost rebates could reduce net savings.

Supporters said HB195 would allow pharmacists to prescribe within their training to improve rural access and reduce costs, while sponsors and witnesses emphasized the bill does not change Alaska abortion law and excludes drugs on the FDA REMS list (including strong mention of mifepristone restrictions).

Trump signs executive order to cut US prescription drug prices by 30-80%. Aimed at bringing fairness and reducing healthcare costs for Americans.

House Bill 813 establishes rules for pharmacy benefits managers in Maryland's managed care organizations.

House members discuss amendments aimed at safeguarding small pharmacies amidst pricing reforms.

Reforms recommended for pharmaceutical sector NBC Online Mon, 06/23/2025 - 18:58

Doctor Papoian highlights 340B program issues including rising costs and reduced provider independence.

Officials discuss transparency gaps in Kansas' 340B drug pricing program impacting patient savings.

Caitlin Lucarello and Sean Gravenger urge federal reforms for Kansas' 340B drug pricing program.

Indiana's SB 118 mandates data reporting for 340B program to enhance transparency.

Panelists address legislative options for improving drug access for patients facing shortages.